Outlook Therapeutics FY26 Q3 net loss narrows to $20.32 million; revenue drops to $9,000

Reuters2026/08/14 11:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Outlook Therapeutics posted a GAAP net loss attributable to common stockholders of USD 20.3 million, or USD 0.15 a share, in Q3 FY2026.
Loss per share narrowed from USD 0.55 a year earlier, reflecting a larger share base.
Revenue fell to USD 9,000 from USD 1.51 million a year earlier, while operating loss narrowed to USD 10.81 million from USD 15.75 million.
Adjusted net loss attributable to common stockholders (non-GAAP) improved to USD 10.9 million, or USD 0.09 a share, from USD 15.8 million.
Management plans a U.S. launch of FDA-approved LYTENAVA by end-2026, targeting potential annual U.S. sales above USD 500 million by 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140715PRIMZONEFULLFEED9810131) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Outlook Therapeutics FY26 Q3 net loss narrows to $20.32 million; revenue drops to $9,000

You may also like

Crypto prices